Bristol-Myers Squibb Company
BMYPharmaceuticals
$61.39+1.35%As of Oct 29vs prior close
- Market cap
- $125.4B
- P/E (TTM)
- 13.6×
- P/E (FY1)
- 9.6×
- From 52W high
- −8.91%
- EPS (LTM)
- $4.52
- Revenue (LTM)
- $50B
- Net margin
- 18.47%
- Dividend yield
- 4.10%
Nomior Score
74
Discounted QualityTop 6% of the scored universe
Growth24
Quality75
Value78
Momentum89
Resilience56
Growth
+10.62%revenue a year over 9 fiscal years
FY16 $19.4BLTM $50B
Connections
Revenue to profitQ3 FY26
17% of revenue became net profit, down 1 pt on a year.
Latest resultsthird quarter of 2026
- Revenue
- $13.1 billion
- Net income
- $2.2 billion
- Adjusted EPS
- $1.35
- Revenue outlook
- $49.75 billion to $50.25 billion
Third quarter revenue rose, led by Growth Portfolio products, while legacy products were mixed with Eliquis growth offset by generic erosion. Earnings per share fell year over year, reflecting acquired IPRD charges and licensing items. The company raised its full-year revenue outlook and lowered its non-GAAP earnings guidance.
Who owns it
6funds, 8 tracked portfolios